1. Neuigkeiten - News

2. Forschungsberichte - Research Focus

3. Aktuelle Projekte - Current Projects

4. Mitarbeiter / Staff

5. Publications

6. Links:

7. Studien / Ki67 in breast cancer

Cserni G, Kalman E, Udvarhelyi N, Papp E, Grote I, Bartels S, Christgen M, Kreipe H, and Kulka J (2023). Evaluation of the routine use of E-cadherin immunohistochemistry in the typing of breast carcinomas: results of a randomized diagnostic study. Histopathology.  In press 

Mouabbi JA, Raghavendra AS, Bassett RL, Jr., Christgen M, Middleton L, Teshome M, Nasrazadani A, Hortobagyi G, Hassan A, Tripathy D, and Layman RM (2023). Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma. Eur J Cancer 191:113250.

Sflomos G, Schaumann N, Christgen M, Christgen H, Bartels S, Kreipe H, Battista L, and Brisken C (2023). Optimized Modeling of Metastatic Triple-Negative Invasive Lobular Breast Carcinoma. Cancers 15:3299

Gluz O, Nitz UA, Christgen M, Kuemmel S, Holtschmidt J, Schumacher J, Hartkopf A, Potenberg J, Luedtke-Heckenkamp K, Just M, Schem C, von Schumann R, Kolberg-Liedtke C, Eulenburg CZ, Schinkothe T, Graeser M, Wuerstlein R, Kates RE, Kreipe HH, and Harbeck N (2023). Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial. JAMA Oncol 9:946-954.

Harbeck N, Nitz UA, Christgen M, Kummel S, Braun M, Schumacher C, Potenberg J, Tio J, Aktas B, Forstbauer H, Grischke EM, Scheffen I, Malter W, von Schumann R, Just M, Zu Eulenburg C, Biehl C, Kolberg-Liedtke C, Deurloo R, de Haas S, Jozwiak K, Hauptmann M, Kates R, Graeser M, Wuerstlein R, Kreipe HH, and Gluz O (2023). De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial. J Clin Oncol 41:3796.

Gluz O, Kuemmel S, Nitz U, Braun M, Ludtke-Heckenkamp K, von Schumann R, Darsow M, Forstbauer H, Potenberg J, Uleer C, Grischke EM, Aktas B, Schumacher C, Zu Eulenburg C, Kates R, Jozwiak K, Graeser M, Wuerstlein R, Baehner R, Christgen M, Kreipe HH, and Harbeck N (2023). Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial. Ann Oncol 34:531.

Christgen M, and Kreipe H (2023). Standardization in the Diagnosis of Invasive Lobular Carcinoma of the Breast. Mod Pathol 36:100163.

Mueller S, Grote I, Bartels S, Kandt LD, Christgen H, Lehmann U, Gluz O, Graeser M, Kates R, Harbeck N,  Kreipe H, Christgen M.* (2023) P53 expression in luminal breast cancer correlates with TP53 mutation and primary endocrine resistance. Mod Pathol. In press.

Mercan C, Balkenhol M, Salgado R, Sherman M, Vielh P, Vreuls W, Polonia A, Horlings HM, Weichert W, Carter JM, Bult P, Christgen M, Denkert C, van de Vijver K, Bokhorst JM, van der Laak J, and Ciompi F* (2022). Deep learning for fully-automated nuclear pleomorphism scoring in breast cancer. NPJ Breast Cancer 8:120.

Graeser M, Gluz O, Biehl C, Ulbrich-Gebauer D, Christgen M, Palatty J, Kuemmel S, Grischke EM, Augustin D, Braun M, Potenberg J, Wuerstlein R, Krauss K, Schumacher C, Forstbauer H, Reimer T, Stefek A, Fischer HH, Pelz E, Zu Eulenburg C, Kates R, Ni H, Kolberg-Liedtke C, Feuerhake F, Kreipe HH, Nitz U, and Harbeck N* (2022). Impact of RNA signatures on pCR and survival after 12-week neoadjuvant pertuzumab plus trastuzumab with or without paclitaxel in the WSG-ADAPT-HER2+/HR- trial. Clin Cancer Res. In press.

Kolberg-Liedtke C*, Feuerhake F, Garke M, Christgen M, Kates R, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Kuemmel S, Wuerstlein R, Graeser M, Nitz U, Kreipe H, Gluz O, and Harbeck N (2022). Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial. Breast Cancer Res 24:58

De Schepper M, Vincent-Salomon A, Christgen M, Van Baelen K, Richard F, Tsuda H, Kurozumi S, Brito MJ, Cserni G, Schnitt S, Larsimont D, Kulka J, Fernandez PL, Rodriguez-Martinez P, Olivar AA, Melendez C, Van Bockstal M, Kovacs A, Varga Z, Wesseling J, Bhargava R, Bostrom P, Franchet C, Zambuko B, Matute G, Mueller S, Berghian A, Rakha E, van Diest PJ, Oesterreich S, Derksen PWB, Floris G, and Desmedt C* (2022). Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer. Mod Pathol 35:1812-1820

Grote I, Bartels S, Christgen H, Kandt L, Lehmann U, Gronewold M, Raap M, Gluz O, Graeser M, Kuemmel S, Nitz U, Harbeck N, Kreipe H, and Christgen M (2022). ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer. Mod Pathol 35:1804-1811

Gluz O, Nitz U, Kolberg-Liedtke C, Prat A, Christgen M, Kuemmel S, Mohammadian MP, Gebauer D, Kates R, Pare L, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Wuerstlein R, Graeser M, Pelz E, Jozwiak K, Zu Eulenburg C, Kreipe HH, and Harbeck N (2022). De-escalated neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Impact of molecular markers and survival analysis of the WSG-ADAPT-TN trial. Clin Cancer Res 28:4995-5003. 

Nitz U, Gluz O, Graeser M, Christgen M, Kuemmel S, Grischke EM, Braun M, Augustin D, Potenberg J, Krauss K, Schumacher C, Forstbauer H, Reimer T, Stefek A, Fischer HH, Pelz E, Zu Eulenburg C, Kates R, Wuerstlein R, Kreipe HH, and Harbeck N (2022). De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 23:625-635.

Nitz UA, Gluz O, Kummel S, Christgen M, Braun M, Aktas B, Ludtke-Heckenkamp K, Forstbauer H, Grischke EM, Schumacher C, Darsow M, Krauss K, Nuding B, Thill M, Potenberg J, Uleer C, Warm M, Fischer HH, Malter W, Hauptmann M, Kates RE, Graser M, Wurstlein R, Shak S, Baehner F, Kreipe HH, and Harbeck N (2022). Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer. J Clin Oncol 40:2557-2567.

de Gregorio A, Janni W, Friedl TWP, Nitz U, Rack B, Schneeweiss A, Kates R, Fehm T, Kreipe H, Christgen M, Kummel S, Trapp E, Wuerstlein R, Hartkopf A, Clemens M, Reimer T, Haberle L, Fasching PA, Gluz O, and Harbeck N (2022). The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C. Br J Cancer 126:1715-1724.

Christgen M, Kandt LD, Antonopoulos W, Bartels S, Van Bockstal MR, Bredt M, Brito MJ, Christgen H, Colpaert C, Cserni B, Cserni G, Daemmrich ME, Danebrock R, Dedeurwaerdere F, van Deurzen CH, Erber R, Fathke C, Feist H, Fiche M, Gonzalez CA, Ter Hoeve ND, Kooreman L, Krech T, Kristiansen G, Kulka J, Laenger F, Lafos M, Lehmann U, Martin-Martinez MD, Mueller S, Pelz E, Raap M, Ravarino A, Reineke-Plaass T, Schaumann N, Schelfhout AM, De Schepper M, Schlue J, Van de Vijver K, Waelput W, Wellmann A, Graeser M, Gluz O, Kuemmel S, Nitz U, Harbeck N, Desmedt C, Floris G, Derksen PW, van Diest PJ, Vincent-Salomon A, Kreipe H. (2022) Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma. J Pathol Clin Res 8:191-205.

Grote I, Bartels S, Kandt L, Bollmann L, Christgen H, Gronewold M, Raap M, Lehmann U, Gluz O, Nitz U, Kuemmel S, Zu Eulenburg C, Braun M, Aktas B, Grischke EM, Schumacher C, Luedtke-Heckenkamp K, Kates R, Wuerstlein R, Graeser M, Harbeck N, Christgen M, Kreipe H. (2021) TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer. Cancer Med 10:8581.

Christgen M, Cserni G, Floris G, Marchio C, Djerroudi L, Kreipe H, Derksen PWB, Vincent-Salomon A. (2021) Lobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors. Cancers 13:3695.

Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials (2021) Graeser M, Schrading S, Gluz O, Strobel K, Würstlein R, Kümmel S, Schumacher C, Grischke EM, Forstbauer H, Braun M, Christgen M, Adams J, Nitzsche H, Just M, Fischer HH, Aktas B, Potenberg J, von Schumann R, Kolberg-Liedtke C, Harbeck N, Kuhl CK, Nitz U. Int J Cancer 148:2614-2627. 

Radner M, von Luttikhuizen j L, Bartels S, Bublitz J, Grote I, Rieger L, Christgen H, Stark H, Werlein C, Lafos M, Steinemann D, Lehmann U, Christgen M, Kreipe H (2021). Chromosome 2q gain and epigenetic silencing of GATA3 in microglandular adenosis of the breast. J Pathol Clin Res.7:220

.

Nitz U, GLuz O, Kreipe H, Christgen M, Kuemmel S, Baehner FL, Shak S, Aktas B, Braun M, Lüdtke-Heckenkamp K, Forstbauer H, Grischke EM, Nuding M, Schumacher C, Krass K, Malter W, Thill M, Warm M, Wuerstlein R, Ronald RE, Harbeck N (2020).
The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combinig static and dynamic biomarker assessments for individualized therapy in early breast cancer. Ther Adv Med Oncol 12:1758835920973130.

Dowsett M, Ellis MJ, Dixon JM, Gluz O, Robertson J, Kates R, Suman VJ, Turnbull AK, Nitz U, Christgen M, Kreipe H, Kuemmel S, Bliss JM, Barry P, Johnston SR, Jacobs SA, MA CX, Smith IE, Harbeck N (2020). Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due the COVID-19 pandemic. NPJ Breast Cancer 6:21.

Kolberg-Liedtke C, Gluz O, Heinisch F, Feuerhake F, Kreipe H, Clemens M, Nuding B, Malter W, Reimer T, Wuerstlein R, Graeser M, Shak S, Nitz U, Kates R, Christgen M, Harbeck N (2020). Association of TILs with clinical parameters, Recurrence Score results, and prognosis in patients with early HER2-negative breast cancer (BC9-a translational analysis of the prospective WSG PlanB trial. Breast Cancer Res 22(1):47.

Schaumann N, Raap M, Hinze L, Rieger L, Schurch CM, Antonopoulos W, Avril S, Krech T, Dammrich M, Kayser G, Puls F, Langer F, Tinguely M, Kreipe H, and Christgen M (2019). Lobular neoplasia and invasive lobular breast cancer: Inter-observer agreement for histological grading and subclassification. Pathol Res Pract 152611.

Gluz O, Kolberg-Liedtke C, Prat A, Christgen M, Gebauer D, Kates R, Pare L, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Kuemmel S, Wuerstlein R, Pelz E, Nitz U, Kreipe HH, and Harbeck N (2019). Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial. Int J Cancer.

Nitz U, Gluz O, Clemens M, Malter W, Reimer T, Nuding B, Aktas B, Stefek A, Pollmanns A, Lorenz-Salehi F, Uleer C, Krabisch P, Kuemmel S, Liedtke C, Shak S, Wuerstlein R, Christgen M, Kates RE, Kreipe HH, and Harbeck N (2019). West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. J Clin Oncol 37:799-808.

Christgen M, Bartels S, Radner M, Raap M, Rieger L, Christgen H, Gluz O, Nitz U, Harbeck N, Lehmann U, and Kreipe H (2019). ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling. Genes Chromosomes Cancer I58:175-185.

Gluz O, Nitz U, Liedtke C, Christgen M, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Bangemann N, Lindner C, Kuemmel S, Clemens M, Potenberg J, Staib P, Kohls A, von Schumann R, Kates R, Schumacher J, Wuerstlein R, Kreipe HH, and Harbeck N (2018). Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results. J Natl Cancer Inst 110:628-637.

Christgen M, Bartels S, Luft A, Persing S, Henkel D, Lehmann U, and Kreipe H (2018). Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer. Virchows Arch 473:577-582.

Raap M, Gronewold M, Christgen H, Glage S, Bentires-Alj M, Koren S, Derksen P, Boelens M, Jonkers J, Lehmann U, Feuerhake F, Kuehnle E, Gluz O, Kates R, Nitz U, Harbeck N, Kreipe H, and Christgen M (2018). Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of Transcription Factor AP 2beta (TFAP2B). Lab Invest 98:117-129.

Bartels S, Christgen M, Luft A, Persing S, Jodecke K, Lehmann U, and Kreipe H (2018). Estrogen receptor (ESR1) mutation in bone metastases from breast cancer. Mod Pathol 31:56-61.

Nitz U, Gluz O, Christgen M, Kates RE, Clemens M, Malter W, Nuding B, Aktas B, Kuemmel S, Reimer T, Stefek A, Lorenz-Salehi F, Krabisch P, Just M, Augustin D, Liedtke C, Chao C, Shak S, Wuerstlein R, Kreipe HH, and Harbeck N (2017). Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. Breast Cancer Res Treat 165:573-583.

Harbeck N, Gluz O, Christgen M, Kates RE, Braun M, Kuemmel S, Schumacher C, Potenberg J, Kraemer S, Kleine-Tebbe A, Augustin D, Aktas B, Forstbauer H, Tio J, von Schumann R, Liedtke C, Grischke EM, Schumacher J, Wuerstlein R, Kreipe HH, and Nitz UA (2017). De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. J Clin OncolJCO2016719815.

Christgen M, Bartels S, van Luttikhuizen JL, Schieck M, Pertschy S, Kundu S, Lehmann U, Sander B, Pelz E, Langer F, Schlegelberger B, Steinemann D, and Kreipe H (2017). Subclonal analysis in a lobular breast cancer with classical and solid growth pattern mimicking a solid-papillary carcinoma. J Pathol Clin Res 3:191-202.

Christgen M, van Luttikhuizen JL, Raap M, Braubach P, Schmidt L, Jonigk D, Feuerhake F, Lehmann U, Schlegelberger B, Kreipe HH, and Steinemann D (2016). Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis. Oncotarget 7:82733-82740.

Christgen M, Steinemann D, Kuhnle E, Langer F, Gluz O, Harbeck N, and Kreipe H (2016). Lobular breast cancer: Clinical, molecular and morphological characteristics. Pathol Res Pract 212:583-597.

Christgen M, Langer F, and Kreipe H (2016). [Histological grading of breast cancer]. Pathologe 37:328-336.

Leo F, Bartels S, Magel L, Framke T, Busche G, Jonigk D, Christgen M, Lehmann U, and Kreipe H (2016). Prognostic factors in the myoepithelial-like spindle cell type of metaplastic breast cancer. Virchows Arch 469:191-201.

Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M, Kraemer S, Aktas B, Kuemmel S, Reimer T, Kusche M, Heyl V, Lorenz-Salehi F, Just M, Hofmann D, Degenhardt T, Liedtke C, Svedman C, Wuerstlein R, Kreipe HH, and Harbeck N (2016). West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. J Clin Oncol 34:2341-2349.

Denkert C, Wienert S, Poterie A, Loibl S, Budczies J, Badve S, Bago-Horvath Z, Bane A, Bedri S, Brock J, Chmielik E, Christgen M, Colpaert C, Demaria S, Van den Eynden G, Floris G, Fox SB, Gao D, Ingold Heppner B, Kim SR, Kos Z, Kreipe HH, Lakhani SR, Penault-Llorca F, Pruneri G, Radosevic-Robin N, Rimm DL, Schnitt SJ, Sinn BV, Sinn P, Sirtaine N, O'Toole SA, Viale G, Van de Vijver K, de Wind R, von Minckwitz G, Klauschen F, Untch M, Fasching PA, Reimer T, Willard-Gallo K, Michiels S, Loi S, and Salgado R (2016). Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Mod Pathol 29:1155-1164.

Christgen M, and Derksen P (2015). Lobular breast cancer: molecular basis, mouse and cellular models. Breast Cancer Res 17:16.

Raap M, Antonopoulos W, Dammrich M, Christgen H, Steinmann D, Langer F, Lehmann U, Kreipe H, and Christgen M (2015). High frequency of lobular breast cancer in distant metastases to the orbit. Cancer Med 4:104-111.

Christgen M, von Ahsen S, Christgen H, Langer F, and Kreipe H (2015). The region-of-interest size impacts on Ki67 quantification by computer-assisted image analysis in breast cancer. Hum Pathol 46:1341-1349.

van Agthoven T, Dorssers LC, Lehmann U, Kreipe H, Looijenga LH, and Christgen M (2015). Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) Drives Proliferation of IPH-926 lobular Carcinoma Cells. PLoS One 10:e0136845.

Muller P, Kreuzaler M, Khan T, Thommen DS, Martin K, Glatz K, Savic S, Harbeck N, Nitz U, Gluz O, von Bergwelt-Baildon M, Kreipe H, Reddy S, Christgen M, and Zippelius A (2015). Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci Transl Med 7:315ra188.

Christgen M, Winkens W, and Kreipe HH (2014). [Determination of proliferation in breast cancer by immunohistochemical detection of Ki-67]. Pathologe 35:54-60.

Christgen M, Noskowicz M, Schipper E, Christgen H, Heil C, Krech T, Langer F, Kreipe H, and Lehmann U (2013). Oncogenic PIK3CA mutations in lobular breast cancer progression. Genes Chromosomes Cancer 52:69-80.

Karch I, Schipper E, Christgen H, Kreipe H, Lehmann U, and Christgen M (2013). Is upregulation of BCL2 a determinant of tumor development driven by inactivation of CDH1/E-cadherin? PLoS One 8:e73062.

Christgen M, Geffers R, Kreipe H, and Lehmann U (2013). IPH-926 lobular breast cancer cells are triple-negative but their microarray profile uncovers a luminal subtype. Cancer Sci 104:1726-1730.

Krech T, Scheuerer E, Geffers R, Kreipe H, Lehmann U, and Christgen M (2012). ABCB1/MDR1 contributes to the anticancer drug-resistant phenotype of IPH-926 human lobular breast cancer cells. Cancer Lett 315:153-160.

Christgen M, Noskowicz M, Heil C, Schipper E, Christgen H, Geffers R, Kreipe H, and Lehmann U (2012). IPH-926 lobular breast cancer cells harbor a p53 mutant with temperature-sensitive functional activity and allow for profiling of p53-responsive genes. Lab Invest 92:1635-1647.

Christgen M, Ballmaier M, Lehmann U, and Kreipe H (2012). Detection of putative cancer stem cells of the side population phenotype in human tumor cell cultures. Methods Mol Biol 878:201-215.

Christgen M, Harbeck N, Gluz O, Nitz U, and Kreipe HH (2012). Recognition and Handling of Discordant Negative Human Epidermal Growth Factor Receptor 2 Classification by Oncotype DX in Patients With Breast Cancer. J Clin Oncol 30:3313-3314.

Vermeulen JF, van de Ven RA, Ercan C, van der Groep P, van der Wall E, Bult P, Christgen M, Lehmann U, Daniel J, van Diest PJ, and Derksen PW (2012). Nuclear Kaiso expression is associated with high grade and triple-negative invasive breast cancer. PLoS One 7:e37864.

Bockmeyer CL, Christgen M, Muller M, Fischer S, Ahrens P, Langer F, Kreipe H, and Lehmann U (2011). MicroRNA profiles of healthy basal and luminal mammary epithelial cells are distinct and reflected in different breast cancer subtypes. Breast Cancer Res Treat.

Wolters M, Kramer MW, Becker JU, Christgen M, Nagele U, Imkamp F, Burchardt M, Merseburger AS, Kuczyk MA, Bach T, Gross AJ, and Herrmann TR (2011). Tm:YAG laser en bloc mucosectomy for accurate staging of primary bladder cancer: early experience. World J Urol 29:429-432.

Christgen M, Geffers R, Ballmaier M, Christgen H, Poczkaj J, Krech T, Kreipe H, and Lehmann U (2010). Down-regulation of the fetal stem cell factor SOX17 by H33342: a mechanism responsible for differential gene expression in breast cancer side population cells. J Biol Chem 285:6412-6418.

Trankenschuh W, Puls F, Christgen M, Albat C, Heim A, Poczkaj J, Fleming P, Kreipe H, and Lehmann U (2010). Frequent and distinct aberrations of DNA methylation patterns in fibrolamellar carcinoma of the liver. PLoS One 5:e13688.

Christgen M, Bruchhardt H, Hadamitzky C, Rudolph C, Steinemann D, Gadzicki D, Hasemeier B, Romermann D, Focken T, Krech T, Ballmaier M, Schlegelberger B, Kreipe H, and Lehmann U (2009). Comprehensive genetic and functional characterization of IPH-926: a novel CDH1-null tumour cell line from human lobular breast cancer. J Pathol 217:620-632.

Kreipe HH, Ahrens P, Christgen M, Lehmann U, and Langer F (2009). [Beyond staging, typing and grading: New challenges in breast cancer pathology.]. Pathologe 31:54-59.

Christgen M, Christgen H, Heil C, Krech T, Langer F, Kreipe H, and Lehmann U (2009). Expression of KAI1/CD82 in distant metastases from estrogen receptor-negative breast cancer. Cancer Sci 100:1767-1771.

Lehmann U, Hasemeier B, Christgen M, Muller M, Romermann D, Langer F, and Kreipe H (2008). Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol 214:17-24.

Christgen M, Bruchhardt H, Ballmaier M, Krech T, Langer F, Kreipe H, and Lehmann U (2008). KAI1/CD82 is a novel target of estrogen receptor-mediated gene repression and downregulated in primary human breast cancer. Int J Cancer 123:2239-2246.

Hasemeier B, Christgen M, Kreipe H, and Lehmann U (2008). Reliable microRNA profiling in routinely processed formalin-fixed paraffin-embedded breast cancer specimens using fluorescence labelled bead technology. BMC Biotechnol 8:90.

Gaedcke J, Traub F, Milde S, Wilkens L, Stan A, Ostertag H, Christgen M, von Wasielewski R, and Kreipe HH (2007). Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer. Mod Pathol 20:864-870.